Asset
STEM BROMELAIN
MediWound Ltd. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06568627 | phase3 | recruiting | 2025-06-01 | 2026-12-01 | MediWound Ltd | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) |
| NCT04817228 | phase2 | completed | 2021-04-21 | 2022-05-06 | MediWound Ltd | A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers |
| NCT03588130 | phase2 | completed | 2019-12-02 | 2021-12-07 | MediWound Ltd | A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers |
| NCT06690177 | phase2 | not_yet_recruiting | 2025-04-30 | 2027-12-30 | MediWound Ltd | Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers |
| NCT02020746 | phase2 | completed | 2014-07-24 | 2017-12-05 | MediWound Ltd | Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds |
FDA applications (0)
This company has no applications containing this asset.